Hongui Cha

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (16)

• B cell-reactive neoantigens boost anti-tumor immunity
  Science Advances 2025 DOI: 10.1126/sciadv.adx8303
  +Save
• MHC II immunogenicity shapes the neoepitope landscape in human tumors
  Nature Genetics 2023 DOI: 10.1038/s41588-022-01273-y
  +Save
• Transcriptional upregulation of <scp>CXCL13</scp> is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma
  Cancer Medicine 2022 DOI: 10.1002/cam4.5460
  +Save
• High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities
  Cancer Research 2022 DOI: 10.1158/0008-5472.can-22-0432
  +Save
• Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology 2022 DOI: 10.1200/jco.21.02010
  +Save
• Synthetic lethality-mediated precision oncology via the tumor transcriptome
  Cell 2021 DOI: 10.1016/j.cell.2021.03.030
  +Save
• Dysregulation of cancer genes by recurrent intergenic fusions
  Genome Biology 2020 DOI: 10.1186/s13059-020-02076-2
  +Save
• Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations
  Scientific Reports 2020 DOI: 10.1038/s41598-020-70168-x
  +Save
• Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity
  Journal for ImmunoTherapy of Cancer 2020 DOI: 10.1136/jitc-2020-001199
  +Save
• Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma
  iScience 2020 DOI: 10.1016/j.isci.2020.101386
  +Save
• Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma
  iScience 2020 DOI: 10.1016/j.isci.2020.101386
  +Save
• HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients
  Annals of Oncology 2020 DOI: 10.1016/j.annonc.2020.04.004
  +Save
• Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing
  European Journal of Cancer 2019 DOI: 10.1016/j.ejca.2019.08.001
  +Save
• Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor
  Journal of Thoracic Oncology 2019 DOI: 10.1016/j.jtho.2019.05.033
  +Save
• Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer
  European Journal of Nuclear Medicine and Molecular Imaging 2019 DOI: 10.1007/s00259-018-4138-5
  +Save
• Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer
  Clinical Cancer Research 2017 DOI: 10.1158/1078-0432.ccr-17-0306
  +Save